Skip to content
Article Rich – Lifestyle
Author:
Orum Therapeutics
Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
August 22, 2026